- You are viewing a Navigating Care library resource.
- Go to Library
Treatment of Acute Promyelocytic Leukemia
Treatment of newly diagnosed acute promyelocytic leukemia (APL) may include:
- all-trans retinoic acid (ATRA) plus (ATO), for low-risk to intermediate-risk disease
- ATRA plus combination chemotherapy, followed by ATO, for high-risk disease
To learn more about these treatments, see the Treatment Option Overview.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
This information is not intended to replace the advice of a doctor.
Navigating Care disclaims any liability for the decisions you make based on this information.
This information was sourced and adapted from Adapted from the National Cancer Institute's
Physician Data Query (PDQ®) Cancer Information Summaries on
www.cancer.gov.
This information updated
November 1, 2024.
Learn more:
- General Information About Acute Myeloid Leukemia
- Stages of Acute Myeloid Leukemia
- Treatment Option Overview
- Treatment of Untreated Acute Myeloid Leukemia
- Treatment of Acute Myeloid Leukemia in Remission
- Treatment of Refractory or Recurrent Acute Myeloid Leukemia
- Treatment of Acute Promyelocytic Leukemia
- Treatment of Recurrent Acute Promyelocytic Leukemia
- To Learn More About Leukemia
Related Articles
- General Information About Acute Myeloid Leukemia
- Stages of Acute Myeloid Leukemia
- Treatment Option Overview
- Treatment of Untreated Acute Myeloid Leukemia
- Treatment of Acute Myeloid Leukemia in Remission
- Treatment of Refractory or Recurrent Acute Myeloid Leukemia
- Treatment of Acute Promyelocytic Leukemia
- Treatment of Recurrent Acute Promyelocytic Leukemia
- To Learn More About Leukemia
See Expert Resources
The Navigating Care Library includes articles about cancer, chemotherapy regimens and drugs from the
the National Cancer Institute and other experts.
